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Subtype selectivityWe present the synthesis of new derivatives of natural products magnolol (1) and honokiol (2) and their
evaluation as allosteric ligands for modulation of GABAA receptor activity. New derivatives were prepared
via metal assisted cross-coupling reactions in two consecutive steps. Compounds were tested by means
of two-electrode voltage clamp electrophysiology at the a1b2c2 receptor subtype at low GABA concen-
trations. We have identiﬁed several compounds enhancing GABA induced current (IGABA) in the range
similar or even higher than the lead structures. At 3 lM, compound 8g enhanced IGABA by factor of
443, compared to 162 and 338 of honokiol and magnolol, respectively. Furthermore, 8g at EC10–20 fea-
tures a much bigger window of separation between the a1b2c2 and the a1b1c2 subtypes compared
to honokiol, and thus improved subtype selectivity.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).esMagnolol (1) and honokiol (2) (Scheme 1) are natural products
belonging to the class of neolignans isolated from Magnolia ofﬁci-
nalis. They have been widely used in Eastern traditional medicine
for treatment of gastric and psychiatric disorders. Therapeutic
applications of Magnolia constituents were summarized compre-
hensively in the recent literature.1 Previously, several studies have
revealed additional pharmaceutical effects of magnolol or honokiol
as anti-angiogenetic,2 antiepileptic,3 neuroprotective,4 or antimi-
crobial and antiproliferative activity.5 Honokiol has been shown
to have somnogenic effects in mice.6 Furthermore, interaction with
the PPARc receptor, involved in treatment of type 2 diabetes, met-
abolic syndrome, and potential anti-inﬂammatory target, was
shown as well.7 In the central nervous system, neolignans interact
with GABAA receptors and modulate their GABA-induced activity
leading to the assumption that their antiepileptic and somnogenic
in vivo effects are mediated by these receptors.8,9
The family of GABAA receptors comprises at least 26 distinct
subtypes.10 These pentameric GABA-gated chloride channels
assemble as homo- or heteropentamers in mammals from a reper-
toire of 19 distinct subunits that belong to eight classes. There are
six a, three b, c and q as well as one d, p, e and h subunits. The most
abundant receptor consists of two a1, two b2 and one c2 subunits.
The GABA binding site in this type of receptor is located at the
extracellular interface between the beta and alpha subunits.11The properties and the pharmacology of the receptor subtypes
depend on the subunit composition.12 In addition to the site for
the endogenous agonist GABA, at which other agonists or antago-
nists such as muscimol, bicuculline or gaboxadol also bind, there
are multiple allosteric binding sites, such as the one for benzodi-
azepines, sites for barbiturates, neurosteroids, and several more.11
Magnolol and analogues have been shown to be allosteric mod-
ulators of GABAA receptors, thus their binding site does not overlap
with the one for GABA, muscimol, bicuculline or gaboxadol.8,9 The
antiepileptic and somnogenic effects of magnolol and honokiol,
respectively, have been connected with the benzodiazepine bind-
ing site because they can be diminished in vivo by the benzodiaz-
epine antagonist ﬂumazenil.4,6 However, neolignans and several
synthetic analogs have been shown to modulate both GABAA
receptors with and without a benzodiazepine binding site.8,9 The
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subunit.12 Recently, it was shown that ﬂumazenil also antagonizes
modulation by aryl pyrazoles in receptors lacking a c2 subunit and,
thus lacking the high afﬁnity benzodiazepine binding site.13 Conse-
quently, ﬂumazenil sensitive effects in vivo do not necessarily indi-
cate that the benzodiazepine binding site is eliciting them.
Certain subunits have been connected with speciﬁc pharmaco-
logical effects: a1 containing receptors are thought to mediate sed-
ative and addictive effects of benzodiazepines, while activity of
ligands at receptors containing a b1 subunit have been proposed
to mediate ataxic effects.14 With respect to GABAA receptor sub-
types, the natural neolignans have been demonstrated as relatively
unselective compounds, and safety concerns have been raised.
Subtype selective synthetic analogs have been proposed to be
potentially useful.9,13,15
Here, we present a facile synthetic strategy towards new mag-
nolol/honokiol derivatives and their evaluation on GABAA recep-
tors. The strength of our approach consists in a simpliﬁcation of
the ﬁnal molecules, allowing their easy synthetic access (compared
to the lead structures), while increasing the biological effect at the
same time.
Magnolol and honokiol are small biaryl isomeric molecules
(Scheme 1). Aromatic ring A is identical for both molecules, while
ring B differs in the position of the hydroxyl group. Our approach
was based on leaving the ring A untouched and carrying out sim-
pliﬁcation of the ring B. Instead of allyl and hydroxyl groups, single
substituents with diverse properties were introduced in all possi-
ble positions of ring B.
Very efﬁciently, magnolol can be accessed by metal or enzyme
mediated oxidative coupling of two 4-allylanisol units and demeth-
ylation.16–18 Such strategy, nevertheless, leads inevitably to the
symmetric product. Unsymmetrical honokiol can be prepared by
bromination of 4-allylanisole and subsequent Suzuki coupling with
4-hydroxyphenylboronic acid. Further modiﬁcations (including O-
allylation, Claisen rearrangement and demethylation) lead to the
desired structure.19 4-Allyl-2-bromoanisole is the key intermediate
which could be used within the synthesis of compounds of our
interest. A drawback of this pathway is the bromination step, where
overbromination of the double bond takes place and debromination
with zinc is necessary, conﬂicting with aspects of atom efﬁciency.
Alternatively, directed ortho-lithiation and introduction of the
boronic acid into 4-allylanisole followed by subsequent coupling
with aryl bromide was reported.20,21 However, we encountered
problems with a reproduction of the protocol.
To circumvent the above outlined limitations, we have devel-
oped a simple two steps protocol, relying on palladium catalyzed
transformations. In the ﬁrst step, the allyl moiety is regioselec-
tively introduced into the more reactive 4-position of 4-bromo-2-
chlorophenol 3 using allylborate. In the second step, Suzuki cou-
pling of 4-allyl-2-chlorophenol 6 with corresponding boronic acids
enabled access to the products of interest. First, we focused ourTable 1
Optimization of the reaction conditions for introduction of the allyl moiety
Entry Pd source Ligand Borate Base Time
1 Pd2dba3 SPhos 4 KF 30
2 Pd2dba3 ±BINAP 4 KF 30
3 Pd2dba3 dppf 4 KF 30
4 PdEn40 dppf 4 KF 30
5 PdEn40 dppf 4 TEA 30
6 PdEn40 dppf 4 NaOAc 30
7 PdEn40 dppf 4 NaOH 30
8 PdEn40 dppf 4 Na2CO3 30
9 PdEn40 dppf 4 K2CO3 30
10 PdEn40 dppf 4 K2CO3 7
11 PdEn40 dppf 5 K2CO3 7attention on optimization of the allylation reaction of 3 and 4
(Scheme 2). Initial experiments utilizing Pd2dba3 as a catalyst, KF
as a base, dioxane/H2O (9:1) mixture as solvent at 150 C
(30 min) under microwave irradiation led to partial success. Three
different ligands were tested (Table 1, entries 1–3) of which dppf
provided most promising results. Full consumption of the starting
material was not observed, however, formation of the desired
product was accompanied by debromination of the starting mate-
rial as side reaction, leading to 2-chlorophenol. Changing the palla-
dium source to heterogenous PdEn40, which can be easily
separated by ﬁltration, led to a decrease of the side reaction; how-
ever, full consumption of 3 could not be achieved (entry 4). Further
investigation revealed that both conversion and side reaction can
be controlled by the base used. Several bases were investigated
(entries 5–9): using triethylamine or sodium acetate led to full
consumption, however debromination was observed (entries 5
and 6). Slight improvement could be achieved by exploiting
sodium carbonate or sodium hydroxide. However, in all cases, side
product was still formed. Full conversion and complete suppres-
sion of the side reaction could be achieved ﬁnally by utilizing
potassium carbonate (entry 9). Reaction time could be successfully
shortened to 7 min and no sign of debromination was observed
(entry 10) facilitating isolation of compound 6 in 77% of yield.
Changing pinacol allylboronate 4 to potassium allytriﬂuoroborate
5 turned out to be beneﬁcial for puriﬁcation of the product, since
pinacolester fragments often contaminated the reaction product
complicating isolation. After optimization of reaction conditions
target compound 6 was ﬁnally isolated in 80% (entry 11).
For the second step, we adopted a modiﬁed protocol by Denton
et al.21 for the coupling of phenyboronic acid with chloro com-
pound 6 under microwave irradiation; 4-allyl-2-phenylphenol 8a
was obtained in 58% of yield (Table 2, entry 1), giving an overall
yield of 46%. For comparison, 8a was also synthesized according
to the above discussed pathway (demethylation/bromination of
4-allylanisole and Suzuki coupling), giving a 15% overall yield after
three steps in our hands.22
This facile two-step protocol was subsequently employed
within the preparation of a small library of compounds to obtain
some preliminary structure activity relationship. Indicative substi-
tution patterns contained weakly electron donating methyl groups(min) Remaining SM Debromination Isolated yield (%)
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Figure 1. Dose–response curves for IGABA potentiation by 8g and honokiol in
a1b1c2 and a1b2c2 using GABA EC10–20.
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Table 2
Synthesized derivatives and their effect at a1b2c2 GABAA receptor
Compound R Yield % IGABA at 3 lM
8a H 58 Inactive
8b o-Me 34 207 ± 33
8c m-Me 39 Inactive
8d p-Me 46 84 ± 11
8e o-OMe 54 Inactive
8f m-OMe 48 136 ± 32
8g p-OMe 34 443 ± 60
8h Lactone 31 Inactive
8i m-COOMe 34 406 ± 70
8j p-COOMe 36 Inactive
8k o-NO2 42 Inactive
8l m-NO2 86 Inactive
8m p-NO2 60 Inactive
2 — — 162 ± 31
1 — — 338 ± 93
402 L. Rycek et al. / Bioorg. Med. Chem. Lett. 25 (2015) 400–403in positions ortho, meta and para, strongly electron donating meth-
oxy groups and methoxycarbonyl as well as nitro groups in all pos-
sible positions as representative electron withdrawing
substituents. Only in a single case we have encountered a problem
with this synthetic route: ortho-methoxycarbonyl substitution
resulted in spontaneous lactonization, since a stable six-membered
ring was formed (Scheme 3, 8h). All compounds were obtained in
moderate to good yields employing the outlined reaction sequence
(Table 2).
The ability of the synthesized honokiol derivatives to modulate
recombinantly expressed a1b2c2 GABAA receptors from rat was
determined in Xenopus laevis oocytes (Table 2). Cells were clamped
at a holding potential of 80 mV. A GABA concentration titrated to
trigger 0.5% of the respective maximum GABA-elicited current of
the individual oocyte (=GABA EC0.5) was applied together with a
ﬁnal concentration of 3 lM of the compound in the measurement
buffer. Use of low GABA concentration allows detecting com-
pounds exerting low efﬁcacy modulation. Compounds were
applied for 20 s. None of the compounds could open the channel
without GABA, so they all are only modulators of the channel.
For details on the electrophysiological recordings see Lüscher
et al.23
Data was obtained from 5 oocytes from at least 4 different
oocyte batches for the active compounds; inactives were measured
with n = 2. The response to 3 lM honokiol (2) was 162 ± 31% of the
response to an EC0.5 GABA concentration and two of the tested
compounds (8g and 8i) possess higher efﬁcacy than the natural
product.A methoxy group inmeta (8f) or para (8g) position is beneﬁcial;
similar behavior was encountered in case of a m-methoxycarbonyl
group (8i).
Surprisingly, also high efﬁcacy was achieved with the o-methyl
group (8b). Compounds with a nitro group did not show any effect.
Since both electron donating (methyl, methoxy) as well as elec-
tron withdrawing (methoxycarbonyl) substituents can increase the
efﬁcacy, a hydrogen bond formation might be involved.
To investigate selectivity, the concentration dependent effect of
8g, the best performing compound at 3 lM (443 ± 60% stimula-
tion), was characterized in a1b2c2 and a1b1c2 receptors at a
higher GABA concentration (at GABA EC10–20) for a better compar-
ison with published literature (EC10–20),8 and compared with hon-
okiol. In a1b2c2 the EC50 value was at approximately 7 lM,
(20 lM for honokiol) and the efﬁcacy at 100 lM was 539 ± 98%.
The EC50 in the b1 containing subtype is 30 lM (20 lM for honok-
iol), the efﬁcacy only 206 ± 60%. The effect of 8g in a mutant
a1b2N265Sc2 receptor was investigated at EC0.5 (see Supplemen-
tary Fig. 1). This mutation in the b2 subunit is known to reduce
the efﬁcacy of several compounds including loreclezole and etom-
idate. With 8g we observed a pronounced drop in response, con-
ﬁrming the key role of b2N265 for the beta subtype selectivity.
The stimulation in the wild type receptor at the same compound
concentration is for comparison 2462%.
Compounds not acting on b1 receptors are thought to be non-
sedative—a desired property for compounds used as anxiolytic or
anticonvulsive medication (Fig. 1).14
In conclusion, we present a rapid and facile synthetic approach
to magnolol and honokiol analogs with unsymmetrical aryl substi-
tution employing consecutive cross coupling reactions. The proto-
col turned out versatile towards highly diverse aryl coupling
partners.
Biological assessment of a ﬁrst small product library revealed
compound 8g to possess a highly interesting combination of
increased potency compared to the natural analogue in the most
abundant a1b2c2 receptor subtype, while showing strongly
reduced responses in the b1 containing subtype that has been con-
nected to ataxic effects.14 Such an action proﬁle has not been
reported for synthetic neolignan derivatives or the natural prod-
ucts, so far, underscoring the relevance of this report.8 It has been
suggested that compounds with antiepileptic or anxiolytic proper-
ties would have fewer side effects if they are inactive in b1 contain-
ing receptor subtypes14 The activity difference we report here for
our lead compound is much more pronounced compared to the
natural products or other synthetic analogs for which this has been
studied.8,9
Based on these preliminary ﬁndings, exploitation of the syn-
thetic strategy towards investigation of further substitution effects
L. Rycek et al. / Bioorg. Med. Chem. Lett. 25 (2015) 400–403 403in an elaborated compound library is presently underway in our
laboratories.
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